Keyword: Global Blood Therapeutics
Global Blood Therapeutics aims to bring a “paradigm shift” to the treatment of sickle cell disease with the launch of Oxbryta.
The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.
A discontinued heart disease drug will be developed for sickle cell, with Roche handing off its inclacumab antibody to Global Blood Therapeutics.
GBT saw its shares dip and climb this morning as those plugging the positive fought it out with those questioning how good its data really are.
California biotech Global Blood Therapeutics is canning its work in idiopathic pulmonary fibrosis (IPF).
With pricing pressure mounting in the diabetes space, insulin specialist Novo Nordisk may be looking to wean itself off its core focus with a rumored buyout for Global Blood Therapeutics, a buy that could help boost its own blood disorder business.
Global Blood Therapeutics will start lining up patients in December for a Phase III, pivotal trial of its GBT440 to treat sickle cell disease.
Global Blood Therapeutics has posted an upbeat update from a clinical trial of its sickle cell disease drug, sparking a 25% jump in the company’s stock price.